等待開盤 03-26 09:30:00 美东时间
+0.050
+0.55%
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:26
BRIEF-Neogenomics Inc - Pantracer Lbx Test Receives Medicare Coverage Under CMS Moldx Program March 16 (Reuters) - Neogenomics Inc NEO.O : NEOGENOMICS INC - PANTRACER LBX TEST RECEIVES MEDICARE COVERAGE UNDER CMS MOLDX PROGRAM Source text: ID:nBw1tXGVma Further company coverage: NEO.O (((( Reuters.B
03-16 19:41
U.S. stock futures higher, Dow up 0.2%. AeroVironment shares down 9.2% after weaker earnings & lowered sales outlook. Other stocks declining in pre-market.
03-11 20:03
BUZZ-U.S. STOCKS ON THE MOVE -Duolingo, AES, NextDecade Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were on track to open lower on Monday as investors
03-02 22:18
BRIEF-Neogen Announces Sale Of Genomics Business To Zoetis March 2 (Reuters) - Neogen Corp NEOG.O : NEOGEN ANNOUNCES SALE OF GENOMICS BUSINESS TO ZOETIS NEOGEN CORP - ZOETIS TO BUY NEOGEN'S GENOMICS BUSINESS FOR $160 MILLION NEOGEN CORP - PROCEEDS FROM SALE TO BE USED FOR DEBT REDUCTION Source text:
03-02 22:14
Zoetis to Buy Neogen’s Animal Genomics Business for $160 Million Zoetis has agreed to buy Neogen’s animal genomics business for $160 million, subject to customary closing adjustments. Neogen’s genomics unit serves customers in more than 120 countries through five labs across the U.S., Brazil, Austra
03-02 20:00
Neogen agrees to sell genomics unit to Zoetis for $160 million Neogen has agreed to sell its global genomics business, GeneSeek, to Zoetis for $160 million, subject to customary closing adjustments. The divestiture, previously disclosed as part of Neogen’s portfolio review, is expected to close by t
03-02 20:00
SPX的看跌期权成交量259.73万张,看涨期权成交量211.55万张,看跌/看涨交易量比率约1.23。
02-18 16:19
BRIEF-Neogenomics Reports Fourth Quarter And Full Year 2025 Results Feb 17 (Reuters) - Neogenomics Inc NEO.O : NEOGENOMICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS Source text: ID:nBw3MNlc4a Further company coverage: NEO.O (( Reuters.Briefs@thomsonreuters.com ;))
02-17 20:36
NeoGenomics Q4 revenue rises, adjusted EPS beats estimates Overview Cancer diagnostics firm's Q4 revenue rose 11% yr/yr, driven by higher-value tests Adjusted EPS for Q4 beat analyst expectations Company successfully resolved RaDaR ST patent litigation Outlook NeoGenomics expects 2026 revenue betwee
02-17 20:13